It is worth mentioning that, via multiplex analysis, it is not possible to differentiate between full-length PRL (23 kDa) with demonstrated pro-tumor, proangiogenic activity, and 16 kDa isoform prolactin [13], which was proposed as an anti-tumor marker [14]. This evidence concerns the gene PRL and neoplasm.